tiprankstipranks
Trending News
More News >
Craneware Plc (GB:CRW)
LSE:CRW
Advertisement

Craneware (CRW) AI Stock Analysis

Compare
24 Followers

Top Page

GB:CRW

Craneware

(LSE:CRW)

Rating:75Outperform
Price Target:
2,789.00p
▲(18.18%Upside)
Craneware's overall stock score is driven primarily by its robust financial performance and positive corporate events, which underscore strong growth potential and strategic positioning. However, a high P/E ratio suggests potential overvaluation, which tempers the overall outlook. Technical indicators also show positive momentum, contributing to a favorable but cautious perspective on the stock.

Craneware (CRW) vs. iShares MSCI United Kingdom ETF (EWC)

Craneware Business Overview & Revenue Model

Company DescriptionCraneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Chargemaster Toolkit, an automated software-as-a-service (SaaS) chargemaster management solution for capturing optimal legitimate reimbursement for providers; Trisus Supply, a solution that utilizes data to identify data gaps between the systems; Physician Revenue Toolkit, a SaaS solution for managing physician group KPIs, charges, codes, RVUs, fee schedules, and related information; Reference Plus, a SaaS solution to perform chargemaster analysis; Pharmacy ChargeLink, a solution to enhance charge capture, pricing, and cost management; integration for chargemaster management, a software that automatically uploads chargemaster changes to the patient billing system for accurate billing; Trisus Pricing Analyzer, a SaaS solution that simplifies the price modelling process; and Online Reference Toolkit and supplies assistant solutions. It also offers InSight Medical Necessity, a SaaS solution that provides medical necessity validation for the United States payors and advance beneficiary notice creation; Trisus Claims Informatics, a software that automates claim and coding reviews; and InSight Audit, a web-based audit management application for healthcare organizations to manage government and commercial audits. In addition, the company provides Trisus Healthcare Intelligence, a cost analytics and resource efficiency platform; trisus pricing transparency; InSight Denials to analyze, track, trend, and report on denial data; and appeals services. Further, it offers customer success management and consulting services; professional services; and sales and marketing, and product and software development services. Craneware plc was incorporated in 1999 and is headquartered in Edinburgh, the United Kingdom.
How the Company Makes MoneyCraneware makes money primarily through the sale of its software solutions, which are provided on a subscription basis. The company's revenue model is largely based on recurring revenue from its software-as-a-service (SaaS) offerings, which provide healthcare organizations with tools for revenue cycle and value cycle management. Key revenue streams include subscription fees, software licenses, and professional services such as implementation and consulting. Significant partnerships with healthcare providers and institutions further contribute to its earnings, as these collaborations help expand its customer base and drive adoption of its solutions.

Craneware Financial Statement Overview

Summary
Craneware exhibits strong financial performance with robust revenue and profit growth, efficient operations, and a stable balance sheet. The company maintains strong cash flow generation, although there is room for improvement in net profit margins and free cash flow growth. Overall, the financial health of Craneware is solid, positioning it well within the healthcare providers & services industry.
Income Statement
85
Very Positive
Craneware demonstrated strong revenue growth of 8.77% from 2023 to 2024, with a solid gross profit margin of 85.7% and a net profit margin of 6.2% in 2024. The EBIT margin was 10.4%, indicating efficient operations, while the EBITDA margin of 28.7% reflects healthy cash generation from operations. Overall, the company shows robust profitability and growth, although net profit margins could be improved.
Balance Sheet
80
Positive
The debt-to-equity ratio improved significantly, reflecting a strong balance sheet with a lower debt burden. Return on equity is moderate at 3.6%, indicating room for improvement in asset utilization. The equity ratio is a healthy 60.4%, suggesting financial stability. The balance sheet shows prudent financial management with a focus on maintaining low leverage.
Cash Flow
78
Positive
Free cash flow decreased from 2023 to 2024, but the company maintains a solid operating cash flow to net income ratio of 3.6, highlighting efficient cash generation relative to earnings. The free cash flow to net income ratio is favorable, showing a strong conversion of earnings into cash. The company should focus on improving free cash flow growth to enhance financial flexibility.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue198.10M189.27M174.02M165.54M75.58M71.49M
Gross Profit171.02M162.20M148.44M142.37M70.20M66.97M
EBITDA36.65M54.26M51.60M47.54M18.48M24.06M
Net Income14.88M11.70M9.23M9.41M12.90M16.84M
Balance Sheet
Total Assets565.96M543.65M576.98M568.79M311.60M115.76M
Cash, Cash Equivalents and Short-Term Investments72.16M34.59M78.54M47.16M235.62M47.85M
Total Debt35.89M40.15M86.69M113.08M1.15M2.02M
Total Liabilities236.84M215.06M249.13M235.77M51.32M47.36M
Stockholders Equity329.12M328.59M327.84M333.02M260.28M68.39M
Cash Flow
Free Cash Flow68.61M24.91M83.20M12.93M13.21M10.96M
Operating Cash Flow69.53M41.86M98.75M26.96M23.54M20.67M
Investing Cash Flow-14.27M-15.81M-15.34M-307.32M-10.32M-9.71M
Financing Cash Flow-46.99M-70.00M-53.28M91.90M174.55M-10.72M

Craneware Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2360.00
Price Trends
50DMA
2153.10
Positive
100DMA
1948.60
Positive
200DMA
2004.60
Positive
Market Momentum
MACD
87.41
Negative
RSI
61.32
Neutral
STOCH
49.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CRW, the sentiment is Positive. The current price of 2360 is above the 20-day moving average (MA) of 2270.50, above the 50-day MA of 2153.10, and above the 200-day MA of 2004.60, indicating a bullish trend. The MACD of 87.41 indicates Negative momentum. The RSI at 61.32 is Neutral, neither overbought nor oversold. The STOCH value of 49.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:CRW.

Craneware Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
£826.45M70.834.50%0.07%6.74%54.83%
71
Outperform
£444.43M62.242.93%126.21%40.66%-55.09%
68
Neutral
£913.38M36.033.41%101.32%11.20%-6.80%
66
Neutral
£1.81B-23.77%7.97%12.94%
61
Neutral
£333.95M8.4911.74%38.80%
59
Neutral
$355.92M-5.04%-1.02%67.70%
52
Neutral
$7.61B0.04-62.94%2.44%16.14%0.33%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
GB:CRW
Craneware
2,340.00
22.85
0.99%
GB:AMS
Advanced Medical Solutions
207.50
-31.54
-13.19%
GB:APH
Alliance Pharma
64.70
27.85
75.58%
GB:PRTC
PureTech Health
142.80
-30.40
-17.55%
GB:SPI
Spire Healthcare
227.00
-13.66
-5.68%
GB:ONT
Oxford Nanopore Technologies PLC
204.20
70.30
52.50%

Craneware Corporate Events

Business Operations and StrategyFinancial Disclosures
Craneware Exceeds FY25 Expectations with Strong Revenue and Profit Growth
Positive
Jul 16, 2025

Craneware plc reported strong financial performance for FY25, with revenue and profitability surpassing market expectations. The company achieved a 12% increase in adjusted EBITDA and a 9% rise in revenue, driven by sales momentum and recurring revenue streams from its Trisus Platform. The partnership with Microsoft and the focus on AI development are expected to enhance market penetration, while strong cash reserves and reduced debt position Craneware well for future growth in the US healthcare market.

The most recent analyst rating on (GB:CRW) stock is a Buy with a £28.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.

M&A TransactionsBusiness Operations and Strategy
Craneware Rejects Bain Capital’s Acquisition Proposal, Citing Undervaluation
Neutral
Jun 11, 2025

Craneware plc announced that Bain Capital Private Equity is no longer pursuing a potential acquisition of the company, following a rejected proposal valuing Craneware at £26.50 per share. The board believes this offer undervalues the company and remains confident in its strategic direction, citing strong trading performance and growth in revenue and earnings. The board attributes recent share price fluctuations to broader market factors rather than company performance, reinforcing its commitment to creating shareholder value.

The most recent analyst rating on (GB:CRW) stock is a Buy with a £28.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.

M&A Transactions
Craneware plc Faces Potential Acquisition by Bain Capital
Neutral
May 16, 2025

Craneware plc has announced that Bain Capital Private Equity is assessing a possible offer for the company. While no formal proposal has been received, Bain Capital has until June 13, 2025, to announce its intentions. This potential offer could significantly impact Craneware’s market positioning and stakeholder interests, pending further developments.

The most recent analyst rating on (GB:CRW) stock is a Buy with a £28.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.

Business Operations and Strategy
Craneware Sees Shift in Major Shareholder Voting Rights
Neutral
May 1, 2025

Craneware plc has announced a change in its major holdings, with Liontrust Investment Partners LLP adjusting its voting rights in the company. The adjustment reflects a decrease in Liontrust’s total voting rights from 10.977% to 10.1601%, indicating a strategic shift in their investment stance. This change may impact the company’s shareholder dynamics and influence future corporate decisions.

Executive/Board ChangesRegulatory Filings and Compliance
Craneware Chair Increases Stake Amid Voting Rights Adjustment
Positive
Apr 28, 2025

Craneware plc announced that its Chair, Will Whitehorn, purchased 1,911 Ordinary Shares, reflecting a minor increase in his stake in the company. This transaction highlights confidence in Craneware’s market position and could positively influence stakeholder perception. Additionally, the company adjusted its total voting rights following the transfer of shares to satisfy employee share options, which now stands at 35,409,802 shares with voting rights.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 17, 2025